- Thermo Fisher Scientific's PPD Clinical Research Business Collaborates with HealthVerity to Expand Real-World Data Capabilities
Apr 13, 2026 · businesswire.com
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) marketplace, to enhance data-driven clinical development and evidence generation for biopharma sponsors. Through the agreement, Thermo Fisher's PPD™ clinical research business will gain enterprise-level access to HealthVerity's TaXOnomy® claims dataset, representing more than 270 million de-identified pa.
- THERMO FISHER SCIENTIFIC'S PPD CLINICAL RESEARCH BUSINESS COLLABORATES WITH HEALTHVERITY TO EXPAND REAL-WORLD DATA CAPABILITIES
Apr 13, 2026
WALTHAM, MASS.--(BUSINESS WIRE)--THERMO FISHER SCIENTIFIC, THE WORLD LEADER IN SERVING SCIENCE, TODAY ANNOUNCED A STRATEGIC DATA COLLABORATION WITH HEALTHVERITY, A LEADING REAL-WORLD DATA (RWD) MARKETPLACE, TO ENHANCE DATA-DRIVEN CLINICAL DEVELOPMENT AND EVIDENCE GENERATION FOR BIOPHARMA SPONSORS. THROUGH THE AGREEMENT, THERMO FISHER'S PPD™ CLINICAL RESEARCH BUSINESS WILL GAIN ENTERPRISE-LEVEL ACCESS TO HEALTHVERITY'S TAXONOMY® CLAIMS DATASET, REPRESENTING MORE THAN 270 MILLION DE-IDENTIFIED PA.
- Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
Feb 18, 2026 · prnewswire.com
SALT LAKE CITY, Feb. 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that the last patient has completed the final study visit (Last Patient Last Visit) in its Phase 3 clinical trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD). The randomized, double-blind, placebo-controlled study enrolled a total of 90 patients with severe PPD, having an average baseline Hamilton depression rating scale (HAM-D) of 28.3.
- LIPOCINE ANNOUNCES LAST PATIENT LAST VISIT IN PIVOTAL PHASE 3 TRIAL OF LPCN 1154 FOR POSTPARTUM DEPRESSION (PPD)
Feb 18, 2026
SALT LAKE CITY, FEB. 18, 2026 /PRNEWSWIRE/ -- LIPOCINE INC. (NASDAQ: LPCN), A BIOPHARMACEUTICAL COMPANY LEVERAGING ITS PROPRIETARY TECHNOLOGY PLATFORM TO DEVELOP INNOVATIVE PRODUCTS WITH EFFECTIVE ORAL DELIVERY, TODAY ANNOUNCED THAT THE LAST PATIENT HAS COMPLETED THE FINAL STUDY VISIT (LAST PATIENT LAST VISIT) IN ITS PHASE 3 CLINICAL TRIAL EVALUATING LPCN 1154 (ORAL BREXANOLONE) FOR THE TREATMENT OF POSTPARTUM DEPRESSION (PPD). THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ENROLLED A TOTAL OF 90 PATIENTS WITH SEVERE PPD, HAVING AN AVERAGE BASELINE HAMILTON DEPRESSION RATING SCALE (HAM-D) OF 28.3.
- Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Jan 20, 2026 · prnewswire.com
SALT LAKE CITY, Jan. 20, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that enrollment and participant dosing have been completed in its Phase 3 clinical trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD). A total of 90 patients were randomized in the study.
- LIPOCINE ANNOUNCES COMPLETION OF ENROLLMENT AND DOSING IN PHASE 3 TRIAL OF LPCN 1154 IN POSTPARTUM DEPRESSION (PPD)
Jan 20, 2026
SALT LAKE CITY, JAN. 20, 2026 /PRNEWSWIRE/ -- LIPOCINE INC. (NASDAQ: LPCN), A BIOPHARMACEUTICAL COMPANY LEVERAGING ITS PROPRIETARY TECHNOLOGY PLATFORM TO DEVELOP INNOVATIVE PRODUCTS WITH EFFECTIVE ORAL DELIVERY, TODAY ANNOUNCED THAT ENROLLMENT AND PARTICIPANT DOSING HAVE BEEN COMPLETED IN ITS PHASE 3 CLINICAL TRIAL EVALUATING LPCN 1154 (ORAL BREXANOLONE) FOR THE TREATMENT OF POSTPARTUM DEPRESSION (PPD). A TOTAL OF 90 PATIENTS WERE RANDOMIZED IN THE STUDY.
- Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Jan 12, 2026 · prnewswire.com
Company on track to report topline results early in the second quarter of 2026 Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available safety data for the 82 randomized No drug discontinuations, excessive sedation, loss of consciousness, or drug-related SAEs reported Study is no longer screening new participants SALT LAKE CITY, Jan. 12, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced the completion of a scheduled independent Data Safety Monitoring Board review of its ongoing Phase 3 clinical trial evaluating LPCN 1154 (oral brexanolone) for the rapid relief treatment of PPD. This was the second of two DSMB reviews planned during the study.
- LIPOCINE REPORTS ENCOURAGING PROGRESS POST SECOND INTERIM SAFETY REVIEW IN PHASE 3 TRIAL OF LPCN 1154 IN POSTPARTUM DEPRESSION (PPD)
Jan 12, 2026
COMPANY ON TRACK TO REPORT TOPLINE RESULTS EARLY IN THE SECOND QUARTER OF 2026 SECOND PLANNED DATA AND SAFETY MONITORING BOARD (DSMB) MEETING EVALUATED ALL AVAILABLE SAFETY DATA FOR THE 82 RANDOMIZED NO DRUG DISCONTINUATIONS, EXCESSIVE SEDATION, LOSS OF CONSCIOUSNESS, OR DRUG-RELATED SAES REPORTED STUDY IS NO LONGER SCREENING NEW PARTICIPANTS SALT LAKE CITY, JAN. 12, 2026 /PRNEWSWIRE/ -- LIPOCINE INC. (NASDAQ: LPCN), A BIOPHARMACEUTICAL COMPANY LEVERAGING ITS PROPRIETARY TECHNOLOGY PLATFORM TO DEVELOP INNOVATIVE PRODUCTS WITH EFFECTIVE ORAL DELIVERY, TODAY ANNOUNCED THE COMPLETION OF A SCHEDULED INDEPENDENT DATA SAFETY MONITORING BOARD REVIEW OF ITS ONGOING PHASE 3 CLINICAL TRIAL EVALUATING LPCN 1154 (ORAL BREXANOLONE) FOR THE RAPID RELIEF TREATMENT OF PPD. THIS WAS THE SECOND OF TWO DSMB REVIEWS PLANNED DURING THE STUDY.
- Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer's Disease Registry to Advance Real-World Evidence in Neurodegenerative Care
Dec 18, 2025 · businesswire.com
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer's Disease Registry to Advance Real-World Evidence in Neurodegenerative Care.
- THERMO FISHER SCIENTIFIC LAUNCHES PPD COREVITAS ALZHEIMER'S DISEASE REGISTRY TO ADVANCE REAL-WORLD EVIDENCE IN NEURODEGENERATIVE CARE
Dec 18, 2025
WALTHAM, MASS.--(BUSINESS WIRE)--THERMO FISHER SCIENTIFIC LAUNCHES PPD COREVITAS ALZHEIMER'S DISEASE REGISTRY TO ADVANCE REAL-WORLD EVIDENCE IN NEURODEGENERATIVE CARE.